- TD Cowen analyst Phil Nadeau reaffirmed a buy rating on Vir Biotechnology, citing the advancement of its hepatitis and oncology pipelines alongside strong financial support.
- The company is progressing its hepatitis D combination program, with value-creating results expected by late 2026, and expanding its oncology portfolio toward trials in 2027.
- Backed by 1.01 billion dollars in cash supporting operations into the second half of 2028, the company is capitalized to reach key clinical milestones.
